Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinacalcet Open Label Study to Reach K/DOQI Levels
NCT00113958Phase 2Completed
- Sponsor
- Amgen
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of cinacalcet in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Primary endpoint: Secondary hyperparathyroidism in people with kidney failure. Status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00113958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00113958.